Viking Therapeutics launches oral maintenance dosing trial of obesity drug VK2735

Bitget2026/10/06 11:05

Viking Therapeutics launched an exploratory trial of oral maintenance dosing for obesity drug candidate VK2735 following initial weight loss from injections. Top-line results from the earlier subcutaneous maintenance phase were already reported; results from the new oral-focused phase are expected in 2027. The study tests whether oral tablets or less-frequent injections can sustain earlier weight loss while tracking safety and drug exposure. Two Phase 3 obesity studies of weekly subcutaneous VK2735 remain fully enrolled, positioning the program for later-stage readouts. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viking Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610060705PR_NEWS_USPR_____LA64478) on October 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.